EGFR and non-small cell lung carcinoma: Zhong et al. [25] reported that the median RFS was significantly longer in the gefitinib group than in the vinorelbine plus cisplatin group among patients with resected stage II to IIIA NSCLC with EGFR mutations (median RFS, 30.8 vs 19.8 months, respectively, P = 0.001).